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Abstract
Antibiotics may induce alterations in the commensal microbiota of the birth canal in pregnant women. Therefore, we studied the effect of
antibiotic administration during pregnancy on commensal vaginal bacterial colonization at gestational week 36. Six hundred and sixty-eight
pregnant women from the novel unselected Copenhagen Prospective Studies on Asthma in Childhood (COPSAC2010) pregnancy cohort
participated in this analysis. Detailed information on oral antibiotic prescriptions during pregnancy ﬁlled at the pharmacy was obtained and
veriﬁed prospectively. Vaginal samples were obtained at pregnancy week 36 and cultured for bacteria. Women who received oral
antibiotics during any pregnancy trimester had an increased rate of colonization by Staphylococcus species in the vaginal samples as
compared with samples obtained from women without any antibiotic treatment during pregnancy (adjusted OR 1.63, 95% CI 1.06–2.52,
p 0.028). Oral antibiotic administration in the third trimester were also associated with increased colonization by Staphylococcus species
(adjusted OR 1.98, 95% CI 1.04–3.76, p 0.037). These bacteriological changes were associated with urinary tract infection antibiotics.
Women treated in the third trimester of pregnancy were more often colonized by Escherichia coli than women without antibiotic
treatment in the third trimester (adjusted OR 1.91, 95% CI 1.04–3.52, p 0.038). This change was associated with respiratory tract
infection (RTI) antibiotics. We did not observe any signiﬁcant changes in vaginal Streptococcus agalactiae (group B streptoccocus) or
Staphylococcus aureus colonization following antibiotic treatment in pregnancy. Antibiotic administration during pregnancy leads to
alterations in the vaginal microbiological ecology prior to birth, with potential morbidity, and long-term effects on the early microbial
colonization of the neonate.
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Oral antibiotic administration during pregnancy leads to alterations in the
vaginal bacterial microbiota before birth, with potential effect on the
woman and fetus.
Introduction
Across various cultural and healthcare settings, antibiotics are
among the most widely used drugs in pregnancy [1]. Prescrib-
ing antibiotics during pregnancy presents a challenge, as
infections need to be treated, but the fetus needs to be
protected from possible side effects of the drugs [2].
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The composition of the commensal vaginal microbiota is not
constant [3]. The commensal microbiota protects against the
proliferation of pathogenic bacteria [4,5]. Numerous factors
may contribute to changes in the vaginal composition, including
antibiotic administration [3]. A few studies have addressed the
effects of local antibiotics on the vaginal microbiota. However,
these had a focus on alterations related to treatment for
bacterial vaginosis and whether the antibiotic treatment was
preventive for preterm birth [3,6,7].
The study objective was to analyse the effect of antibiotic
use during pregnancy on vaginal colonization at week 36 of
pregnancy. We hypothesized that maternal antibiotic use in
pregnancy is an environmental risk factor for both short-term
and long-term changes in the vaginal microbial composition.
Materials and Methods
Ethics
The study followed the principles of the Declaration of
Helsinki, and was approved by the Ethics Committee for
Copenhagen (H-B-2008-093) and the Danish Data Protection
Agency (2008-41-2599). Written informed consent was
obtained from all participants.
The study is reported in accordance with the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [8].
Study population
The novel Copenhagen Prospective Studies on Asthma in
Childhood 2010 (COPSAC2010) is an ongoing Danish cohort
study of 738 pregnant women and their children followed
prospectively from pregnancy week 24 in a protocol designed
from the ﬁrst COPSAC birth cohort (COPSAC2000) [9–11].
Participants were recruited unselectively during 2009–2010,
and the only exclusion criteria were chronic cardiac, endocri-
nological, nephrological or lung disease other than asthma.
Data validation and quality control followed the guidelines for
Good Clinical Practice. Data were collected during visits to the
clinical research unit, and stored in a dedicated online
database, double-checked against source data, and locked.
Bacterial samples
Vaginal samples from asymptomatic pregnant women were
characterized by culture at pregnancy week 36. Swabs were
sampled from the fornix posterior of the vagina with ﬂocked
swabs (ESWAB ﬂocked regular; SSI Diagnostica, Hillerød,
Denmark), and were cultured within 24 h according to
standard methods on non-selective and selective media (SSI
Diagnostica). One set of blood agar plates (5% horse blood)
and chocolate agar plates (including lysed blood cells) were
used for general culture. These were incubated aerobically at
37°C for 18–20 h. The other set of blood agar and chocolate
agar plates were incubated under micro-aerophilic conditions
(5% CO2, 3% H2, 5% O2, and 87% N2) at 37°C for 48 h.
Additionally, one HBT plate was used for selection of
Gardnerella vaginalis incubated under micro-aerophilic condi-
tions at 37°C for 48 h. Subsequently, microbial identiﬁcation
was performed according to growth on selective media,
characteristics of colonies, and cellular morphology. All
bacterial identiﬁcations were conﬁrmed biochemically with
VITEK-2 (BioMerieux, Marcy l’Etoile, France). The isolates
were characterized at the species level, and grouped in the
analyses at the genus level. We used a cut-off value of <5%
women colonized for a genus to be analysed. Group B
streptococcus (GBS; Streptococcus agalactiae), Escherichia coli
and Staphylococcus aureus were analysed at the species level.
Information on antibiotic use
Detailed information on oral antibiotic ingestion during
pregnancy was obtained by interviews with the participants
at the COPSAC research clinic at pregnancy weeks 24 and 36,
and 1 week postpartum. This information was validated against
data in the Danish Medical Agency’s Register, which included
records on all drug prescriptions ﬁlled at the pharmacy, to
minimize recall bias and exclude antibiotics collected but not
ingested.
Oral antibiotic ingestion was analysed both as a dichoto-
mized (yes/no) and as a categorized variable by treatment
indication (A—urinary tract infection (UTI) antibiotics
(J01CA08, J01EBxx, and J01XExx); B—respiratory tract infec-
tion (RTI) antibiotics (J01CAxx, excluding J01CA08, J01CExx,
and J01FAxx); C—other antibiotics (J01CFxx, D06BXxx,
J01AAxx, and P01ABxx)). Only treatments with oral antibiot-
ics administered before the vaginal sampling date were used in
this analysis. Analyses were performed on antibiotic use at any
time-point during pregnancy and on use in the third trimester
of pregnancy.
Covariates
Information on race, maternal age at birth, parity, number of
older siblings at home, asthma, alcohol intake, smoking, cat or
dog in the home and household income during pregnancy was
obtained by the study physicians during the scheduled visits to
the COPSAC clinics at gestational weeks 24 and 36 and
1 week postpartum.
Statistical analysis
The chi-square test, Student’s t-test or the Wilcoxon rank sum
test was used for simple associations in the demographic
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characteristics. The associations between antibiotics and
bacterial cultures were analysed by multiple logistic regression
with each of the other vaginal bacteria identiﬁed in the samples
and socio-economic confounders found in the baseline char-
acteristics (Table 1) as covariates. Estimates were expressed
as ORs, with the untreated group as reference and with
corresponding 95% CIs. A signiﬁcance level of 0.05 was used in
all types of analysis. Missing data were treated as missing
observations. Data processing was conducted with SAS
version 9.3 for Windows (SAS Institute, Cary, NC, USA).
Diversity and composition analyses of the microbiology and
the association with antibiotic treatment were performed with
data-driven methods by pattern recognition (partial least-
squares discriminant analysis) and evaluated from receiver
operating characteristic curves showing speciﬁcity as com-
pared with sensitivity. Data processing was performed with
MATLAB R2009b 7.9.
Results
Demographics
The women were categorized on the basis of their use of
antibiotics in pregnancy. There were no signiﬁcant differences
between the groups with respect to ethnicity, maternal age,
household income, alcohol intake, previous pregnancies, or
number of older siblings in the home. We observed signiﬁ-
cantly higher rates of asthmatic (31% vs. 23%) and smoking
mothers (11% vs. 5%), and of mothers living with a cat or a dog
in the home (44% vs. 31%), in the group treated with
antibiotics (Table 1). Therefore, all risk analyses were adjusted
for maternal asthma, smoking, and cat and dog in the home, as
well as all other vaginal bacteria identiﬁed in the samples.
Baseline characteristics
Complete data on antibiotic administration and week 36
vaginal cultures were available for 668 pregnant women. Of
these women, 226 (34%) received antibacterial drugs prior to
sampling (369 treatments in total). The most frequently
administered antibacterial agents during pregnancy were UTI
antibiotics (19% of the women). Eighteen per cent of the
women were treated with RTI antibiotics. Only 1% received
other antibacterial drugs, so we did not analyse this group
further (Table 2).
Vaginal cultures
Gram-positive bacteria dominated the colonization. Among 668
samples, we found Staphylococcus species in 79% (526), Coryne-
bacterium species in 41% (276), Lactobacillus species in 40% (264),
yeast in 29% (197), Enterococcus species in 24% (162),Micrococcus
species in 17% (112), Streptococcus species in 18% (117), E. coli in
12% (78), and Kocuria species in 5% (34) (see Table S1 for more
details). Ten per cent (64) of the women were colonized by
GBS. Eighteen per cent (117) of the women were colonized by
S. aureus. For 4% (24) of the samples, we did not obtain any visual
growth.
Oral antibiotic use and vaginal colonization
Oral antibiotic administration at any pregnancy trimester was
associated with a signiﬁcantly increased rate of colonization
(83%) by Staphylococcus species in the vaginal samples as
compared with women without antibiotic treatment (76%).
No other bacterial genus was signiﬁcantly affected by overall
treatment in pregnancy. Eighty-six per cent of women treated
with antibiotics in the third trimester, and 77% of women
without antibiotic treatment in the third trimester, were
colonized by Staphylococcus species. Nineteen per cent of
women treated with oral antibiotics in the third trimester, and
TABLE 1. Baseline characteristics for the study cohort, and
grouped according to antibiotic treatment during pregnancy
All
Antibiotic treatment
pYes No
All, % (N) 668 34 (226) 66 (442) –
Caucasian, % (n) 96 (637) 96 (214) 96 (423) 0.91
Age (years) at birth,
mean (SD)
32.3 (4.4) 32.2 (4.8) 32.4 (4.2) 0.61
Asthma history, % (n)a 26 (174) 31 (70) 23 (104) 0.04
Smoking, % (n) 7 (48) 11 (24) 5 (24) 0.01
Alcohol >1 unit/week, % (n) 5 (30) 4 (10) 5 (20) 0.96
Household
income—high, % (n)b
37 (242) 33 (72) 40 (170) 0.09
Nulliparity, % (n) 47 (316) 45 (102) 48 (214) 0.42
Older children (no.),
mean (SD)
0.8 (0.8) 0.8 (0.9) 0.8 (0.8) 0.22
Cat or dog in the
household, % (n)
35 (236) 44 (99) 31 (137) <0.01
SD, standard deviation.
aHistory of doctor-diagnosed asthma.
b>€110 000/year.
Signiﬁcant values are in bold.
TABLE 2. Prevalence of antibiotic administration in preg-
nancy prior to vaginal sampling at pregnancy week 36; 668
women
Drug group
Any
trimester,
% (n)
First
trimester,
% (n)
Second
trimester,
% (n)
Third
trimester,
% (n)
Antibacterial 34 (226) 13 (85) 16 (110) 14 (95)
UTI antibiotic 19 (129) 7 (44) 10 (65) 8 (55)
Pivmecillinam 17 (111) 5 (35) 8 (55) 7 (47)
Sulphamethizole 3 (22) 2 (12) 1 (7) 1 (5)
Nitrofurantoin 2 (10) 0 (2) 1 (5) 1 (4)
RTI antibiotic 18 (123) 7 (44) 8 (52) 7 (45)
Penicillin 14 (96) 5 (34) 6 (39) 4 (30)
Ampicillin derivate 5 (33) 2 (11) 2 (14) 2 (13)
Macrolide 2 (11) 0 (3) 0 (3) 1 (5)
Other antibiotic 1 (8) 1 (4) 0 (2) 0 (2)
Dicloxacillin 1 (5) 0 (2) 0 (2) 0 (1)
Metronidazole 0 (2) 0 (1) 0 (0) 0 (1)
Tetracycline 0 (1) 0 (1) 0 (0) 0 (0)
RTI, respiratory tract infection; UTI, urinary tract infection.
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10% of women without antibiotic treatment in the third
trimester, were colonized by E. coli (Table 3).
The increase in vaginal Staphylococcus species was mainly
associated with treatment with UTI antibiotics. Eighty-ﬁve
per cent 85% of women treated with UTI antibiotics at any
point of pregnancy, and 76% of women without any antibiotic
treatment in pregnancy, were colonized with Staphylococcus
species (adjusted OR 1.90, 95% CI 1.08–3.33, p 0.026). Nine-
ty-three per cent of women treated with UTI antibiotics in the
third trimester, and 77% of women without any antibiotic
treatment in the third trimester, were colonized with Staph-
ylococcus species (adjusted OR 3.97, 95% CI 1.38–11.43,
p 0.011). There were no signiﬁcant effects on Staphylococcus
species of other antibiotic groups (Fig. 1).
The increase in vaginal E. coli after treatment in the third
trimester was mainly associated with RTI antibiotics. Twen-
ty-two per cent of women treated with RTI antibiotics in the
third trimester, and 10% of women without any antibiotic
treatment in the third trimester, were colonized with E. coli
(adjusted OR 2.47, 95% CI 1.12–5.46, p 0.025). UTI antibiotics
administered in the third trimester also showed a tendency to
increase vaginal E. coli, but not signiﬁcantly (Fig. 2).
We did not observe any signiﬁcant changes in the rate of
vaginal GBS colonization following antibiotic treatment. Nine
per cent of antibiotic-treated women, and 10% of women
without any antibiotic treatment in pregnancy, were colonized
with GBS.
We did not observe any signiﬁcant changes in the rate of
vaginal S. aureus colonization in women treated with antibiot-
ics in pregnancy.
No changes in the overall diversity and composition of the
commensal vaginal microbiota were observed. We were not
able to differentiate between the treated and the untreated
women by evaluating the receiver operating characteristic
curves (from partial least-squares discriminant analysis).
Discussion
Principal ﬁndings
Antibiotic use was associated with increased vaginal coloniza-
tion by Staphylococcus species, especially after UTI treatment.
Vaginal colonization by E. coli increased after antibiotic
administration during the third trimester, RTI antibiotics
contributing most to this. Antibiotic administration did not
signiﬁcantly inﬂuence the vaginal GBS or S. aureus colonization
TABLE 3. Multivariate ORs with 95% CIs for each bacterial genus cultured from the vaginal samples for women treated with any
type of oral antibacterial drug either in the third trimester (pregnancy weeks 26–36) or in any trimester (pregnancy weeks 0–36).
Estimates are adjusted for all other vaginal bacteria identiﬁed in the samples, maternal asthma, smoking, and cat or dog in the
home
Microorganism
Antibiotic use in third trimester (pregnancy
weeks 26–36)
N = 95 (668)
Antibiotic use in any trimester (pregnancy
weeks 0–36)
N = 226 (668)
Adjusted OR (95% CI) p Adjusted OR (95% CI) p
Staphylococcus spp. 1.98 (1.04–3.76) 0.037 1.63 (1.06–2.52) 0.028
Corynebacterium spp. 0.84 (0.53–1.33) 0.467 1.02 (0.73–1.44) 0.901
Lactobacillus spp. 1.06 (0.67–1.68) 0.808 0.99 (0.70–1.39) 0.936
Enterococcus spp. 0.79 (0.46–1.37) 0.407 1.23 (0.83–1.80) 0.301
Micrococcus spp. 0.82 (0.44–1.52) 0.524 0.93 (0.59–1.45) 0.749
Streptococcus spp. 0.75 (0.40–1.38) 0.352 0.74 (0.47–1.17) 0.194
Escherichia coli 1.91 (1.04–3.52) 0.038 0.93 (0.55–1.56) 0.773
Kocuria spp. 0.89 (0.30–2.64) 0.826 0.88 (0.40–1.91) 0.739
p = 0.011 p = 0.550
UTI Antibiotic
N = 55
RTI Antibiotic
N = 45
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FIG. 1. Associations between the use of oral urinary tract infection
(UTI) antibiotics and respiratory tract infection (RTI) antibiotics in the
third trimester, pregnancy weeks 26–36, and vaginal colonization by
Staphylococcus species. Estimates are adjusted for all other vaginal
bacteria identiﬁed in the samples, maternal asthma, smoking, and cat or
dog in the home.
ª2013 The Authors
Clinical Microbiology and Infection ª2013 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, 629–635
632 Clinical Microbiology and Infection, Volume 20 Number 7, July 2014 CMI
rates. Approximately one-third of the pregnant women were
treated with antibiotics, which is quite a high proportion in a
country such as Denmark, which has low consumption of
antibiotics in general.
Strengths and limitations
The main strength of this study is the design of the
COPSAC2010 pregnancy cohort, which is a replication and
extension of the COPSAC2000 cohort design. The pregnant
women were recruited and closely monitored at the
dedicated COPSAC clinical research centre from gestational
week 24.
The high reliability of the data obtained on maternal history
of antibiotic administration is a further strength of this study.
This information was obtained through interviews with the
participants during their visit to the COPSAC clinic, and
validated against recordings from the Danish Central Medical
Register. This is a highly accurate register for data validation, as
antibiotics may only be prescribed by an authorized physician,
and can only be purchased from authorized pharmacies.
A limitation of the study is that we relied solely on culture,
with which only a percentage of bacterial species can be
successfully identiﬁed [12]. Bacteriological culture methods are
vulnerable to the time from sampling to analysis, as well as
bacterial growth conditions. This poses a limitation for
assessment of the composition of the commensal vaginal
microbiota, and may also explain the samples without growth,
as these were all handled in the same manner as the other
samples, and did not differ regarding time of transport; also,
none of the women was receiving ongoing antibiotic treat-
ment. The culture methods used were not able to identify
Mycobacterium species and Ureaplasma species, which would
also have been of clinical interest.
Another limitation of our study is that bacterial samples
were analysed at the genus level. However, subclassiﬁcation
and analyses at the species level would result in loss of power
and the issue of multiple testing, which was controlled for in
the current study by adjusting the analyses for all other vaginal
bacteria identiﬁed in the samples and socio-economic
confounders.
Interpretation
Staphylococcus species were found to colonize 79% of the
women. This number conforms with previous studies in
pregnant women. We found less Lactobacillus species coloni-
zation than expected; only 40% of the women were colonized.
We believe that this is atributable to overgrowth of other
bacteria, which makes the detection of Lactobacillus less
successful. However, the remaining bacteria represented in
the samples matched the expected values [13].
Only 10% of women carried GBS, which is a low frequency
as compared with other reports [14,15]. This percentage was
not signiﬁcantly affected by any antibiotic treatment. Even
treatment with RTI antibiotics in the third trimester did not
eradicate the vaginal GBS at week 36 of pregnancy. GBS
screening is not applied in Denmark, and, in our study, oral
antibiotic use during pregnancy did not affect the GBS
colonization rate, conﬁrming previous reports [16,17]. This
is interpreted as recolonization from the gastrointestinal tract,
which serves as the primary reservoir for GBS [18].
The increase in the Gram-positive Staphylococcus species is
mainly a result of treatment with UTI antibiotics. These drugs
are effective against Gram-negative bacteria, and have previ-
ously been shown to increase the amount of staphylococci
found in non-pregnant women [19]. A similar mechanism may
explain the increase in E. coli following treatment with RTI
antibiotics in the third trimester. Most antibiotics in this group
are effective against Gram-positive bacteria; hence the increase
in Gram-negative E. coli. No long-term changes were found
after treatment in the ﬁrst or second trimester. Thus, it seems
that the microbial ecology returns to equilibrium in the
months following treatment.
Women living with a cat or a dog in the household were at
higher risk of being colonized by vaginal E. coli and of being
treated with antibiotics in pregnancy, as we previously reported
[20]. All estimates remained signiﬁcant after adjustment for this
p = 0.073 p = 0.025
N = 55 N = 45
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FIG. 2. Associations between the use of oral urinary tract infection
(UTI) antibiotics and respiratory tract infection (RTI) antibiotics in the
third trimester; pregnancy weeks 26–36, and vaginal colonization by
Escherichia coli. Estimates are adjusted for all other vaginal bacteria
identiﬁed in the samples, maternal asthma, smoking, and cat or dog in
the home.
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confounder, suggesting a different mechanism for this
observation.
Ascending pathogens from the vagina constitute the most
likely source of intrauterine infection, and abnormal coloniza-
tion of the genital tract has been associated with subsequent
preterm birth [21]. Vaginal E. coli has likewise been described
as an independent risk factor for preterm birth [22,23] and a
major contributor to neonatal infection [24,25]. Preventive
strategies leading to increased antibiotic use in pregnancy may
therefore indirectly increase adverse pregnancy outcomes and
early-onset neonatal sepsis, caused by an increased rate of
vaginal colonization by E. coli.
Ultimately, the newborn child may receive a different and
perhaps non-favourable composition of microbiota through
vertical transmission during birth. We have previously
reported that reduced diversity of the neonatal faecal micro-
biota and overgrowth with staphylococci is associated with
atopic sensitization at school age [26]. Likewise we reported
that both the use of antibiotics and vaginal colonization by
staphylococci in pregnancy were associated with wheezy
disorders in childhood [27,28]. In this way, alterations in the
vaginal microbiota may act as a vector for atopic disease in
childhood. It is plausible that general alterations in the bacterial
composition on all colonized human surfaces might occur, as
observed for the vaginal microbiota following antibiotic
treatment.
The overall composition of bacteria showed no differences
in a data-driven model. Even though the levels of some bacteria
were signiﬁcantly increased after treatment, the remaining
bacteria seem to equalize the differences in composition.
Conclusion
Antibiotic administration during pregnancy may lead to
alterations in the vaginal microbiological ecology prior to
birth. We found preferential increases in Staphylococcus species
and E. coli. A changed vaginal microbiota in pregnant women
may lead to infections, with potential morbidity, preterm
delivery, neonatal infection, and long-term effects on the early
microbial colonization of the neonate.
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